서울분당병원 / 임유진, 김인아*
Abstract
PURPOSE:
Although gene expression profiling provides critical information, knowledge remains limited regarding the differential effects of molecular subtype on clinical course. This study evaluated the impact of molecular status on long-term patterns of failure in patients with non-metastatic breast cancer.
METHODS:
We analyzed data from 1181 individuals with invasive breast cancer undergoing surgery plus PORT from 2003 to 2011. Molecular subtypes were defined as luminal A (LA), luminal B (LB)-HER2(-), LB-HER2(+), HER2, and triple-negative (TN) based on the 2013 St. Gallen Consensus criteria. Competing risks analysis and baseline hazard rate function plots were used to explore subtype-specific recurrence patterns.
RESULTS:
The 10-year overall survival rates of LA, LB-HER2(-), LB-HER2(+), HER2, and TN groups were 96, 93, 94, 84, and 85%, respectively (P < 0.001). Distant metastatic events differed significantly according to molecular subtype (P < 0.001). In competing risks regression analysis, initial development of distant metastasis was the highest with TN tumors, followed by HER2, LB-HER2(-), and LB-HER2(+) subtypes (P = 0.005). Regarding preferential sites of distant metastasis, the risk of initial brain metastasis was significantly higher with HER2 tumors, followed by TN tumors (P = 0.001). A low-level but sustained metastatic risk increment was observed in luminal tumors, whereas TN and HER2 subtypes showed a short-term risk surge within 5 years.
CONCLUSION:
From the significant impact of molecular profile on distant metastasis, subtype-specific individualization of systemic treatment and close surveillance are suggested. The preferential and long-term risk of brain metastasis in the HER2 subtype underlines the importance of alternative anti-HER2 therapies.
Author information
Lim YJ1, Lee SW1, Choi N1, Kwon J1, Eom KY1,2, Kang E2, Kim EK2, Kim SW3, Kim JH2, Kim YJ2, Kim SH2, Park SY2, Kim JS1, Kim IA4,5.
1 Department of Radiation Oncology, Seoul National University Bundang Hospital, 82, Gumi-Ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-Do, 13620, Republic of Korea.
2 Breast Care Center, Seoul National University Bundang Hospital, Seoul National College of Medicine, Seongnam, Korea.
3 Department of Surgery, Daerim St. Mary's Hospital, Seoul, Korea.
4 Department of Radiation Oncology, Seoul National University Bundang Hospital, 82, Gumi-Ro 173 beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-Do, 13620, Republic of Korea. inah228@snu.ac.kr.
5 Breast Care Center, Seoul National University Bundang Hospital, Seoul National College of Medicine, Seongnam, Korea. inah228@snu.ac.kr.